Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers.

An open study to investigate the PAF-acether antagonist activity of Tanakan in healthy male volunteers examined the effect of a single 15-ml oral dose on ex vivo platelet aggregation induced by adrena